Oxford Asset Management reduced its position in Endocyte, Inc. (NASDAQ:ECYT) by 42.4% during the first quarter, Holdings Channel reports. The institutional investor owned 120,559 shares of the biopharmaceutical company’s stock after selling 88,701 shares during the period. Oxford Asset Management’s holdings in Endocyte were worth $310,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Parametric Portfolio Associates LLC increased its position in shares of Endocyte by 57.8% in the first quarter. Parametric Portfolio Associates LLC now owns 162,329 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 59,454 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Endocyte by 26.7% in the first quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 28,110 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Endocyte by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares in the last quarter. Algert Global LLC bought a new position in shares of Endocyte during the first quarter worth approximately $345,000. Finally, Stoneridge Investment Partners LLC increased its position in shares of Endocyte by 40.0% in the first quarter. Stoneridge Investment Partners LLC now owns 57,406 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16,399 shares in the last quarter. Institutional investors and hedge funds own 33.04% of the company’s stock.

Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte, Inc. (ECYT) opened at 1.59 on Tuesday. The company’s market capitalization is $67.53 million. The stock’s 50 day moving average is $2.22 and its 200-day moving average is $2.34. Endocyte, Inc. has a 1-year low of $1.50 and a 1-year high of $3.53.

Endocyte (NASDAQ:ECYT) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.01. Endocyte had a negative net margin of 59,808.57% and a negative return on equity of 29.67%. The business had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the company posted ($0.24) EPS. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts expect that Endocyte, Inc. will post ($0.89) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Oxford Asset Management Cuts Position in Endocyte, Inc. (ECYT)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/06/20/oxford-asset-management-cuts-position-in-endocyte-inc-ecyt.html.

A number of equities analysts have recently issued reports on ECYT shares. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. Wedbush reiterated an “outperform” rating on shares of Endocyte in a research note on Thursday, May 11th. Cowen and Company reiterated a “buy” rating on shares of Endocyte in a research note on Wednesday, April 5th. Finally, ValuEngine downgraded shares of Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.58.

Endocyte Company Profile

Want to see what other hedge funds are holding ECYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endocyte, Inc. (NASDAQ:ECYT).

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.